Acoramidis reduces all-cause mortality in ATTR-CM
AHA 2024 - Daniel Judge discusses the findings from the ATTRibute-CM-OLE trial, the open-label extension study of ATTRibute-CM with the oral TTR stabilizer acoramidis in patients with ATTR-CM.
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Gautam Nayak, MD
Gautam Nayak, MD
Frederick Ruberg, MD
Kibum Kim, PhD
